Pafuramidine is among the first drugs to be considered for fast track status under new and more stringent State Food and Drug Administration (SFDA) rules recently introduced in China.
Eric Sorkin, chairman and CEO of Immtech said: “This is a significant milestone for Immtech to work in China to accelerate the approval and availability of Pafuramidine as a treatment for pneumocystis pneumonia (PCP). As the most populous nation in the world, China is well positioned to support and benefit from important efforts to combat PCP and other devastating infectious diseases.”